NCT03370276 2026-03-10
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
H. Lee Moffitt Cancer Center and Research Institute
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Duke University
Merck KGaA, Darmstadt, Germany